Theralase Technologies Inc (TLTFF)

[123414]

We have plenty of money in the bank. The warrants will provide additional money for the till. Expect more warrants to get extended as we have recently seen. The continued insider buying is saying no PP will be required for the ongoing PH2 study.

https://www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123170-eau-2020-immunotherapy-and-beyond-new-options-for-non-muscle-invasive-bladder-cancer.html" rel="nofollow" target="_blank" >https://www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123170-eau-2020-immunotherapy-and-beyond-new-options-for-non-muscle-invasive-bladder-cancer.html

The data is getting more attention during this heads down time. Progress of the Phase 2 study is simmering nicely.

We are dealing with oncology research, which takes time. And a pandemic is also in the consideration.

We are approved for the PH2 in the US things are getting quietly accomplished.

Theralase Receives FDA IND Authorization

Toronto, Ontario – May 19, 2020,

Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce today that the Company has received Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) authorization to conduct a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) in the United States.

https://theralase.com/pressrelease/theralase-receives-fda-ind-authorization/